オキソリン酸

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

• 注意書き

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P270：この製品を使用する時に、飲食または喫煙をしないこ と。

  P301+P312：飲み込んだ場合：気分が悪い時は医師に連絡する こと。

  P501：内容物/容器を．．．に廃棄すること。

オキソリン酸 価格

MSDS Information

• Oxolinic acid

オキソリン酸 化学特性,用途語,生産方法

• 外観

  白色～わずかにうすい黄色, 結晶性粉末～粉末

• 溶解性

  1mol/l 水酸化ナトリウム 200～330g/kg、＜10g/kg アセトン, 酢酸エチル, ヘキサン,メタノール、0.003mg/l 水。水酸化ナトリウム溶液に溶け、水にほとんど溶けない。

• 用途

  窒素複素環系殺菌剤 尿路防腐薬

• 用途

  ニューキノロン系抗菌剤です。 DNA ジャイレースを阻害し、抗菌作用を示し ます。

• 効能

  抗菌薬, 核酸合成阻害薬

• 農薬用途

  動物薬、合成抗菌剤

• 説明

  Bacterial DNA gyrase is a heterodimeric type II topoisomerase that negatively supercoils circular double-stranded DNA. Oxolinic acid is a quinolone antibiotic that inhibits bacterial DNA gyrase, but not eukaryotic topoisomerases, reversibly binding gyrase subunit A in gyrase-DNA complexes, blocking supercoiling activity and inhibiting DNA synthesis at 0.5-5 μg/ml. Oxolinic acid also blocks neuronal uptake of dopamine in mammals (IC₅₀ = 4.3 μM), leading to an increase in locomotor activity.

• 化学的特性

  Crystalline Solid

• 使用

  Oxolinic acid is a quinolone antibiotic used for studies on DNA winding and coiling and for studies on dopaminergic neurotransmission processes. It is used to study new transmissible resistance mechanisms qnrA, qnrB, qnrS, and aac(6′)Ib-cr, in Escherichia

• 定義

  ChEBI: A quinolinemonocarboxylic acid having the carboxy group at position 7 as well as oxo and ethyl groups at positions 4 and 1 respectively and a dioxolo ring fused at the 5- and 6-positions. A synthetic antibiotic, it is used in veterinary medicine for the tr atment of bacterial infections in cattle, pigs and poultry.

• 抗菌性

  Like nalidixic acid, this drug is effective with respect to Gram-negative microorganisms and is used for the same indications. Synonyms of this drug are nidantin, prodoxol, ocolin, uroxol, and others.

• 一般的な説明

  Chemical structure: quinolone

• 応用例（製薬）

  An oral 4-quinolone with a tricyclic structure. Its antibacterial spectrum is very similar to that of nalidixic acid, but it is more active againstEnterobacteriaceae (MIC 0.25–2 mg/L). Grampositive bacteria, Ps. aeruginosa and anaerobes are resistant.
  After repeated doses of 750 mg twice daily, mean plasma concentrations are initially very low, but steady state is reached at the third day and Cmax is around 3.5 mg/L. Administration with food delays absorption. Binding to plasma protein is about 80%. It undergoes complex biotransformation, and an enterohepatic cycle may account for the increase in the apparent elimination half-life from 4 to 15 h over 7 days of treatment as well as for the 20% of dose which can be recovered from the feces. About 50% of the dose appears in the urine in the first 24 h, partly in the form of metabolites, some of which display antibacterial activity.
  Side effects common to the quinolones occur frequently. About one-quarter of patients treated with 750 mg every 12 h suffer nausea and vomiting or restlessness and insomnia. Its only use is in the treatment of lower urinary tract infections.

• 安全性プロファイル

  Moderately toxic by ingestion. Low toxicity by skin contact. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx.

• 純化方法

  Purify the acid by recrystallisation from aqueous Me2CO, 95% EtOH or dimethylformamide. It has UV 220, (255.5sh), max 259.5, 268, (298sh, 311sh), 321 and 326nm [ 14.8, (36.8sh), 38.4, 38.4, (6.4sh, 9.2sh), 10.8 and 11.2 x 103]. [Kaminsky & Mettzer J Med Chem 11 160 1968, Beilstein 17 H 6, 17 I 3, 17 II 202, 17 III/IV 13, 17/1 V 11.]

オキソリン酸 上流と下流の製品情報

オキソリン酸 生産企業

Global(362)Suppliers

オキソリン酸 スペクトルデータ(IR1、IR2、MS)

14698-29-4, オキソリン酸 キーワード